Case Report Feasibility and Long-Term Results of Versajet® Hydrosurgery Technique as First Treatment of Neonates Affected by Giant Congenital Melanocytic Nevi (GCMN): a Single Center Ten-Years Experience
by Eleonora Cesca1, Sara Maria Cravano2*, Alessandra Cazzuffi1, Dora Persichetti Proietti1, Cristian Succi1, Enrica Rossi1, Maria Elena Michelini1, Claudio Vella1
1University Hospital Sant’Anna of Ferrara, Italy
2IRCCS Sant'Orsola-Malpighi Polyclinic, University of Bologna, Italy
*Corresponding author: Sara Maria Cravano, IRCCS Sant'Orsola-Malpighi Polyclinic, University of Bologna, Italy
Received Date: 14 June 2024
Accepted Date: 25 June 2024
Published Date: 28 June 2024.
Citation: Cesca E, Cravano SM, Cazzuffi A, Proietti DP, Succi C, et al. (2024) Feasibility and Long-Term Results of Versajet® Hydrosurgery Technique as First Treatment of Neonates Affected by Giant Congenital Melanocytic Nevi (GCMN): a Single Center Ten-Years Experience. Arch Pediatr 9: 313. https://doi.org/10.29011/2575-825X.100313
Abstract
Giant congenital melanocytic nevus (GCMN) is defined as a melanocytic congenital lesion that will reach a diameter ≥ 20 cm in adulthood, and that presents as a brown lesion, with flat or mammilated surface, well-demarcated borders and hypertrichosis. It may associate with severe complications such as malignant melanoma, neurocutaneous melanosis, and psychosocial disorders. Treatment may include surgical and non-surgical procedures, psychological intervention and/or clinical follow-up. The only absolute indication for surgery is the development of a malignant neoplasm on the lesion.
A Retrospective observational study was conducted including all newborns (6 patients, median age 14 days, range 8-25 days) who underwent Versajet® hydrosurgery during the first month of life for GCMN at our Center in the period between November 2009 and December 2020. Treatment modalities, early and late complications, cosmetic results (with an average five years follow-up), malignant transformation and psychosocial impact were examinated. The effectiveness of Versajet® hydrosurgery varied according to the site and extension of the lesions. Compliance to treatment was close to 100%. This study aimed to assess the short and long-term results of Versajet® hydrosurgery as initial treatment of GCMN in newborns. It showed to be safe and effective both at short and long term follow-up. However, patients reported a negative impact of the residual disease on their social life. Neurocutaneous melanosis is considered the most challenging associated condition to manage.
Keywords: Giant congenital melanocytic nevi (GCMN); Melanoma; Neurocutaneous Melanosis; Versajet® Hydrosurgery.
© by the Authors & Gavin Publishers. This is an Open Access Journal Article Published Under Attribution-Share Alike CC BY-SA: Creative Commons Attribution-Share Alike 4.0 International License. Read More About Open Access Policy.